Carbamazepine is metabolized to an active metabolite known as carbamazepine-10,11-epoxide, or The widely used antiepileptic drug carbamazepine is an iminostilbene derivative that is structurally similar to the tricyclic antidepressant imipramine. It was approved in the United States in 1974 for management of seizure disorders in adults and in 1979 for use in children older than 6 years. Current indications include complex partial, generalized tonicclonic, and mixed seizures. 1 Carbamazepine is also indicated for treatment of trigeminal or glossopharyngeal neuralgia and is used to manage other conditions such as resistant schizophrenia, bipolar disorder, ethanol withdrawal, aggression, and posttraumatic stress disorder. [2] [3] [4] [5] Like other classic antiepileptic drugs, the therapeutic and most of the toxic effects of carbamazepine are better correlated with plasma concentrations than with dose. Routine monitoring of carbamazepine plasma concentrations and comparison with a therapeutic range such as 4-12 μg/mL (17-51 μmol/L) is recommended to optimize dose. An active metabolite of carbamazepine, carbamazepine-10,11-epoxide, commonly known as the "epoxide" metabolite is equipotent to carbamazepine and, therefore, contributes significantly to therapeutic benefits of carbamazepine therapy. However, the epoxide metabolite is not routinely monitored and is not reflected in the commonly targeted therapeutic range. Indeed, there is currently no commercially available immunoassay for determining the concentration of the epoxide metabolite. Instead, measurement of the epoxide metabolite requires chromatographic analysis, which is not widely available. [6] [7] [8] [9] Chemical structures of carbamazepine and the epoxide metabolite are shown in ❚Figure 1❚.
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For most patients, the concentration of the epoxide metabolite at steady state is approximately 15% to 20% of the Upon completion of this activity you will be able to:
• describe why for certain patient populations simultaneous determination of both the parent drug carbamazepine and its active metabolite carbamazepine-10,11-epoxide is important for proper patient management.
• discuss the limitation of carbamazepine determination by various immunoassays associated with cross-reactivity of carbamazepine metabolite with the antibody.
• apply liquid chromatography combined with mass spectrometry to determine accurately the concentrations of both carbamazepine and its active metabolite carbamazepine-10,11-epoxide.
• explain a novel approach to determining carbamazepine-10,11-epoxide level using 2 different carbamazepine immunoassays with substantially different cross-reactivity toward epoxide. The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit ™ per article. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module.
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total carbamazepine concentration. The proportion of epoxide metabolite may be significantly higher in carbamazepine overdose, renal failure, and altered pharmacokinetics (eg, in patients coadministered interacting drugs such as valproic acid). In these cases, total carbamazepine concentrations may fall within the recommended therapeutic range, but patients may experience dose-related toxic effects due to an inappropriately high concentration of the epoxide metabolite that is not detected by the assay used for monitoring carbamazepine. 10 Therapeutic monitoring with immunoassays for which the cross-reactivity with the epoxide metabolite is low will not be sensitive to imbalance in the relative proportion of epoxide and may lead to inappropriate dose adjustments and inaccurate interpretations, particularly for patients with moderate to severe renal insufficiency. 11 Immunoassays designed to measure carbamazepine levels have variable cross-reactivity for the epoxide metabolite. Chen and Khayam-Bashi 12 showed excellent correlation between carbamazepine concentrations obtained by gas chromatography and a widely used fluorescence polarization immunoassay. The cross-reactivity of the epoxide metabolite with the VITROS carbamazepine reagent system (Ortho-Clinical Diagnostics, Rochester, NY) is reported to be 0%, whereas cross-reactivity in the Dade Dimension carbamazepine assay (Dade Behring, Deerfield, IL) is reported to be 94%. 13 Parant et al 14 also reported high cross-reactivity of the particle-enhanced turbidimetric inhibition immunoassay (PETINIA; Siemens Healthcare Diagnostics, Deerfield, IL) carbamazepine assay with the epoxide metabolite and negligible cross-reactivity with the EMIT 2000 carbamazepine assay.
Herein we describe a mathematical approach for estimating the carbamazepine and epoxide metabolite concentrations that was developed by using combinations of results generated by 3 different carbamazepine immunoassays with low or high cross-reactivity for the epoxide metabolite and samples prepared with known concentrations of each compound. The mathematical approach was validated with residual patient specimens containing carbamazepine and the epoxide metabolite.
Materials and Methods
Carbamazepine and carbamazepine-10,11-epoxide were obtained from Sigma Chemical (St Louis, MO). Stock solutions (1 mg/mL) were prepared in high-performance liquid chromatography grade methanol. Residual patient plasma samples were obtained and deidentified according to protocols approved by the University of Utah Institutional Review Board, Salt Lake City.
Three different immunoassay reagent systems designed to quantify carbamazepine were included: PETINIA, ADVIA, and a cloned enzyme donor immunoassay (CEDIA). The PETINIA, performed using a Dimension Vista analyzer, and the ADVIA assay, performed using a Centaur instrument, were obtained from Siemens Healthcare Diagnostics. The PETINIA is a homogeneous particle-enhanced turbidimetric inhibition immunoassay that incorporates a monoclonal detection antibody. The reported analytic measurement range is 0.5 to 20 μg/ mL, and cross-reactivity with the epoxide metabolite exceeds 90%. The ADVIA Centaur carbamazepine assay is a competitive immunoassay using direct chemiluminescent technology. This assay also incorporates a monoclonal detection antibody against carbamazepine. The reported analytic measurement range is 0.25 to 18 μg/mL, and cross-reactivity with the epoxide metabolite is 7.3%. The CEDIA carbamazepine assay, obtained from Roche Diagnostics (Indianapolis, IN), was performed with a Modular P 800 analyzer (Roche). The CEDIA carbamazepine assay uses recombinant DNA technology to produce a unique homogeneous immunoassay system. The reported analytic measurement range is 0.5 to 20 μg/mL, and cross-reactivity with the epoxide metabolite is 7.3%, similar to the ADVIA reagent system. Herein we report results from 3 sets of experiments. In the first set of experiments, aliquots of a drug-free plasma pool were supplemented with various amounts of the epoxide metabolite to achieve final epoxide concentrations in the plasma ranging from 0.0 to 25.0 μg/mL. The small amount of methanol (microliter quantity) used to prepare the stock solutions was tested and shown to not interfere with any of the carbamazepine immunoassays used (data not shown). The apparent carbamazepine concentration in these prepared samples was measured in triplicate using all 3 carbamazepine immunoassays (PETINIA, ADVIA, and CEDIA). The mean value was used to calculate the actual percentage of crossreactivity from the epoxide metabolite in the carbamazepine assay. By using the percentage of cross-reactivity with each assay, we created mathematical equations to estimate concentrations of carbamazepine and the epoxide metabolite.
In the second set of experiments, 2 drug-free plasma pools were supplemented with carbamazepine to achieve final carbamazepine concentrations of 8.0 and 12.0 μg/mL (34 and 51 μmol/L). Aliquots of both carbamazepine-containing pools were further supplemented with various concentrations of epoxide (0.0-6.0 μg/mL). Apparent carbamazepine concentrations were measured using all 3 immunoassays. This experiment was performed to evaluate mathematical equations derived from the first experiment and how well the equations estimated true concentrations of carbamazepine and the epoxide metabolite in plasma specimens with known concentrations.
Finally, concentrations of carbamazepine and the epoxide metabolite were determined with 15 patient specimens using the immunoassays described and liquid chromatography combined with tandem mass spectrometry (LC-MS/MS). The LC-MS/MS method was designed to detect and quantify 5 antiepileptic drugs and metabolites with 1 internal standard. The method was performed using a Waters Acquity UPLC/ TQD system (Waters, Milford, MA), MassLynx software (Waters), and a Waters HSS T3 1.8-μm, 2.1 × 50-mm column. The injection volume was 5 μL, and chromatography was performed at room temperature with mobile phases of 75% water and 25% acetonitrile (Fisher Scientific, Pittsburgh, PA), both with 0.1% formic acid (Fisher Scientific), at a flow rate of 0.65 mL/min. At 1.4 minutes, the mobile phase proportions were reversed for 1 minute. An electrospray ionization interface, multiple reaction monitoring, and positive ion mode were used. The resolution of both quadrapoles was maintained at unit mass resolution with a peak width at half height of 0.7 atomic mass unit. Two transitions for each analyte and the single internal standard were included in the method: The mathematical equations were used to calculate concentrations of carbamazepine and the epoxide metabolite in these specimens. Then concentrations of the epoxide metabolite, as well as parent carbamazepine, that were estimated mathematically were compared with the concentrations obtained by the LC-MS/MS method.
Results
As determined with 5 concentrations of carbamazepine-10,11-epoxide, the cross-reactivity of the epoxide with the PETINIA for carbamazepine varied from 86.6% to 105.7% with an average cross-reactivity of 96.2%. The cross-reactivity of epoxide with the ADVIA varied from 5.3% to 7.7% with an average cross-reactivity of 6.5%. Because this assay has low cross-reactivity with the epoxide metabolite, aliquots of a drug-free plasma sample containing 5.5 μg/mL or more epoxide metabolite were required to generate measurable apparent carbamazepine concentrations, and, hence, only those values were used to calculate the average cross-reactivity of the epoxide with the ADVIA. Similarly, owing to low cross-reactivity of the epoxide with the CEDIA, only results for samples that contained at least 5.5 μg/mL of the epoxide metabolite were used for the calculation of average cross-reactivity with the epoxide (10.5%) in the CEDIA ❚Table 1❚. These observed cross-reactivities are consistent with reported values, with the exception of the CEDIA, for which the 10.5% cross-reactivity observed was slightly higher than the 7.3% cross-reactivity with the epoxide that is reported by the manufacturer.
By taking advantage of the high level of cross-reactivity for the epoxide observed with the Vista (PETINIA) and the low level of cross-reactivity observed with the ADVIA Centaur, we proposed equations to estimate epoxide and carba-mazepine concentrations based on the apparent carbamazepine values obtained by both assays. The average cross-reactivity of epoxide with the PETINIA was 96.2%. Therefore, carbamazepine concentration observed by the PETINIA can be expressed by the following equation: x + 0.962 y = a, where "a" represents observed carbamazepine concentration by the PETINIA, "x" represents the true concentration of carbamazepine, and "y" represents the true concentration of epoxide. Similarly, if the observed carbamazepine concentration by the ADVIA is considered as "b", then, x + 0.065 y = b, because the average cross-reactivity of the epoxide with the ADVIA carbamazepine assay was 6.5%. Therefore, we have 2 unknowns (carbamazepine concentration represented as "x" and epoxide concentration represented as "y") and 2 simultaneous equations: supplemented aliquots of a drug-free plasma pool with known amounts of carbamazepine and epoxide and determined carbamazepine concentrations using all 3 carbamazepine immunoassays ❚Table 2❚. We calculated carba-mazepine and epoxide concentrations using equations 1 and 2 and equations 1 and 3 and observed good correlation between target and calculated concentrations of carbamazepine and the epoxide metabolite ❚Table 3❚.
We also analyzed 15 specimens from patients receiving carbamazepine by using LC-MS/MS (reference method) and all 3 carbamazepine immunoassays ❚Table 4❚. Then we used equations 1 and 2 and equations 1 and 3 to calculate carba-mazepine and epoxide concentrations ❚Table 5❚. Another simple approach to estimate the epoxide concentration is to subtract the carbamazepine value obtained by the ADVIA from the carbamazepine value observed by the PETINIA. The true carbamazepine concentration in a specimen is very similar After calculating the value of y, the value of x can be easily determined by subtracting 0.96 y from the value of a.
Carbamazepine values obtained by the PETINIA and CEDIA can also be used to calculate epoxide and true carbamazepine concentrations. To evaluate usefulness of these equations in calculating carbamazepine and carbamazepine-10,11-epoxide concentrations, we to the carbamazepine value obtained by the ADVIA ❚Table 6❚. This is because the ADVIA has low cross-reactivity with the epoxide, whereas the PETINIA carbamazepine value actually represents carbamazepine plus the epoxide value owing to very high cross-reactivity of the epoxide with the PETINIA. 
Discussion
It is recognized that patients with renal insufficiency who are treated with carbamazepine may show disproportionately high concentrations of carbamazepine-10,11-epoxide and an increased risk of dose-related carbamazepine toxic effects. Potter and Donnelly 10 suggested that routine monitoring of the epoxide metabolite may have clinical benefits. Unfortunately, many routine therapeutic drug monitoring methods are not obtained by using the ADVIA from the carbamazepine value obtained by the PETINIA, we observed the following regression equation: y = 0.9779 x -0.1419 (r = 0.90; n = 15) Therefore, by using this simple approach, we can make a fairly good estimate of carbamazepine and epoxide concentrations without using sophisticated and expensive LC-MS/MS technology.
As A more accurate approach for calculating carbamazepine and epoxide concentrations is to use carbamazepine values obtained by using the PETINIA and ADVIA and then applying equations 1 and 2 (Table 5 ). When we For a small laboratory that has only 1 chemistry analyzer, it is possible that 2 carbamazepine immunoassays can be available, if it is an open channel analyzer using user-defined parameters so that the epoxide concentration can be calculated by using the observed carbamazepine concentration using both assays. For example, the EMIT 2000 carbamazepine assay can be performed in the Dimension analyzer, which is different from the PETINIA marketed by the manufacturer of the instrument (Siemens Healthcare Diagnostics). Parant et al 14 reported significant cross-reactivity of hydroxyzine and its metabolite with the PETINIA carbamazepine assay, but they eliminated this interference by using the EMIT 2000 assay using the same Dimension analyzer. Therefore, our approach can also be implemented in a small laboratory with 1 analyzer available as long as the analyzer has open channels and the capability of implementing user-defined test.
Mathematical equations to calculate carbamazepine and epoxide concentrations from 2 carbamazepine values obtained by 2 different immunoassays are an effective means of detecting epoxide concentrations for patients treated with carbamazepine who are at risk of clinically significant epoxide accumulations or who have signs and symptoms of carbamazepine toxicity. If necessary, these values can be verified by sending specimens to a reference laboratory. sensitive to the epoxide and will, therefore, fail to identify patients at risk for dose-related carbamazepine toxic effects.
Additional populations of patients that may benefit from therapeutic monitoring of the epoxide metabolite are important to consider as well. For example, elderly patients, for whom there is a poor correlation between plasma carbamazepine concentration and dosage, are likely to accumulate epoxide metabolite. Indeed, it has been shown that age-related changes in pharmacokinetics of carbamazepine in most elderly patients alter the proportion of epoxide and are associated with lower dose requirements than predicted from median population kinetics. 15 Patients with genetic polymorphisms in microsomal epoxide hydroxylase, the enzyme primarily associated with production of the epoxide metabolite, may benefit from epoxide monitoring to define the metabolic phenotype and optimize dose. 16 Finally, drug-drug interactions may place a patient at risk for inappropriate epoxide concentrations that would justify therapeutic monitoring of the metabolite. Lamotrigine, which is often coadministered with carbamazepine in treating epilepsy, provides an example. In a study of 8 patients (5 men and 4 women; ages 19-31 years) managed initially with carbamazepine, the authors observed an increase in plasma epoxide concentration of 45% after adding lamotrigine (median daily dosage, 200 mg) to the regimen. In 4 patients, such increases in the epoxide concentration were associated with dose-related toxic effects. 17 Quetiapine also interacts with carbamazepine and increases the concentration of epoxide metabolite, possibly by inhibiting the epoxide hydroxylase enzyme. 18 It is also documented that valproic acid increases the incidence of carbamazepine-related toxic effects as well, due to accumulation of the epoxide metabolite in the plasma, despite total plasma carbamazepine concentrations within the therapeutic range. 14 The need for determination of carbamazepine and epoxide concentrations is clinically significant for select patient populations and clinical scenarios, wherein accumulation of the active epoxide level is likely. Although there are immunoassays that will cross-react with the epoxide metabolite to account for the amount of total active drug in circulation, there are currently no immunoassays for determination of the epoxide metabolite concentration independent of the carbamazepine concentration. As such, sophisticated techniques such as LC-MS/MS, which are not widely available to most clinics, are required. In the case of suspected carbamazepine toxic effects due to accumulation of epoxide metabolite, a rapid determination of both carbamazepine and epoxide concentrations may be critically needed.
The approach described herein allows estimation of true carbamazepine and epoxide concentrations in human plasma using 2 different carbamazepine immunoassays that have differing cross-reactivities for carbamazepine and the epoxide metabolite. The only requirement is that the cross-reactivity of each assay with the epoxide be significantly different. In
